Sign in Subscribe

$MAIA

MAIA Biotechnology (MAIA) Initiates Phase 3 Trial for Ateganosine in NSCLC, Receives FDA Fast Track Designation

11 Dec 2025 SEC Filing 8-K $MAIA

MAIA Biotechnology (MAIA) Initiates Phase 3 Trial for Ateganosine in NSCLC, Receives FDA Fast Track Designation

MAIA Biotechnology (MAIA) filed an 8-K on Dec 11, 2025, disclosing Phase 3 trial initiation and FDA Fast Track designation for Ateganosine in NSCLC.

MAIA Biotechnology (MAIA) Receives FDA Fast Track Designation for Ateganosine in NSCLC

10 Dec 2025 SEC Filing 8-K FDA $MAIA

MAIA Biotechnology (MAIA) Receives FDA Fast Track Designation for Ateganosine in NSCLC

MAIA Biotechnology (MAIA) received FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.